Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Evaluation of the Oncomine Pan-Cancer Cell-Free Assay for Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid in Patients with Central Nervous System Malignancies

(2021) Mauli Shah et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer

(2020) Charu Aggarwal et al.   CLINICAL CANCER RESEARCH

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

(2020) J.H. Shim et al.   ANNALS OF ONCOLOGY

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

(2020) Philip C. Mack et al.   CANCER

Integrating genomic features for non-invasive early lung cancer detection

(2020) Jacob J. Chabon et al.   NATURE

Liquid biopsy for early stage lung cancer moves ever closer

(2020) Christian Rolfo et al.   Nature Reviews Clinical Oncology

Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers

(2020) Manuel Caitano Maia et al.   Nature Reviews Urology

Is tissue still the issue in detecting molecular alterations in lung cancer?

(2020) Chong‐Kin Liam et al.   RESPIROLOGY

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

(2020) Naiyer A. Rizvi et al.   JAMA Oncology

Personalized Medicine: Recent Progress in Cancer Therapy

(2020) Valentina Gambardella et al.   Cancers

Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers

(2020) Diego Fernández-Lázaro et al.   Diagnostics

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

(2020) M.C. Liu et al.   ANNALS OF ONCOLOGY

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

(2020) Christian Rolfo et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Liquid biopsies: Potential and challenges

(2020) Isabel Heidrich et al.   INTERNATIONAL JOURNAL OF CANCER

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review

(2020) Andrew J. Piper-Vallillo et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

(2020) Mariantonia Nacchio et al.   Journal of Thoracic Disease

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

(2020) Lee S. Schwartzberg et al.   npj Precision Oncology

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

(2020) J.J. Lin et al.   ANNALS OF ONCOLOGY

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

(2020) Barzin Y. Nabet et al.   CELL

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

(2020) Sandra Ortiz-Cuaran et al.   CLINICAL CANCER RESEARCH

Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer

(2020) Mei-Mei Zheng et al.   Journal of Thoracic Oncology

Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice

(2020) Charu Aggarwal et al.   Nature Reviews Clinical Oncology

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin

(2020) Ryan Woodhouse et al.   PLoS One

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

(2020) Shumei Kato et al.   Nature Communications

Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade

(2020) Qu Zhang et al.   Cancer Discovery

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

(2020) Maria Jose Serrano et al.   Cancer Discovery

Understanding EGFR heterogeneity in lung cancer

(2020) Antonio Passaro et al.   ESMO Open

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

(2019) Zhijie Wang et al.   JAMA Oncology

Liquid biopsy and minimal residual disease — latest advances and implications for cure

(2019) Klaus Pantel et al.   Nature Reviews Clinical Oncology

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC

(2019) Ibiayi Dagogo-Jack et al.   Journal of Thoracic Oncology

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

(2019) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Promises, promises, and precision medicine

(2019) Michael J. Joyner et al.   JOURNAL OF CLINICAL INVESTIGATION

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium

(2019) B T Li et al.   ANNALS OF ONCOLOGY

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer

(2019) Yaxiong Zhang et al.   Journal for ImmunoTherapy of Cancer

Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol

(2019) Laure Sorber et al.   Cancers

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

(2019) Ibiayi Dagogo-Jack et al.   CLINICAL CANCER RESEARCH

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

(2019) Jhanelle E. Gray et al.   CLINICAL CANCER RESEARCH

Prospective detection of mutations in cerebrospinal fluid, pleural effusion and ascites of advanced cancer patients to guide treatment decisions

(2019) Sergio Villatoro et al.   Molecular Oncology

LBA5_PROsimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

(2019) S S Ramalingam et al.   ANNALS OF ONCOLOGY

O.01 Challenges of Interpreting NGS Liquid Biopsy (LB) Results in Advanced NSCLC: Are ESCAT and OncoKB Scales Reliable?

(2019) A. Russo et al.   Journal of Thoracic Oncology

PD2.01 PD-L1 and Other Potential Predictive Biomarkers Measured in Plasma by RT-PCR in cfRNA and cfDNA to Monitor Clinical Responses in Metastatic Lung Cancer Patients

(2019) L. Raez et al.   Journal of Thoracic Oncology

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

(2019) Pedram Razavi et al.   NATURE MEDICINE

Role of liquid biopsy in oncogene-addicted non-small cell lung cancer

(2019) Matteo Canale et al.   Translational Lung Cancer Research

Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions

(2019) Laure Sorber et al.   Molecular Diagnosis & Therapy

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer

(2018) N Guibert et al.   ANNALS OF ONCOLOGY

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

(2018) Sarah B. Goldberg et al.   CLINICAL CANCER RESEARCH

False positive plasma genotyping due to clonal hematopoiesis

(2018) Yuebi Hu et al.   CLINICAL CANCER RESEARCH

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

(2018) Gregory P. Kalemkerian et al.   JOURNAL OF CLINICAL ONCOLOGY

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

(2018) Travis A. Clark et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

(2018) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

(2018) Neal I. Lindeman et al.   Journal of Thoracic Oncology

IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)

(2018) Christian Rolfo et al.   Journal of Thoracic Oncology

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab

(2018) Nicolas Guibert et al.   LUNG CANCER

Detection and localization of surgically resectable cancers with a multi-analyte blood test

(2018) Joshua D. Cohen et al.   SCIENCE

Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules

(2018) Mingzhi Ye et al.   Journal of Thoracic Disease

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

(2018) J Mateo et al.   ANNALS OF ONCOLOGY

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Liquid Biopsy and Lung Cancer

(2018) Pasquale Pisapia et al.   ACTA CYTOLOGICA

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

(2018) J Zugazagoitia et al.   ANNALS OF ONCOLOGY

LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

(2018) E S Kim et al.   ANNALS OF ONCOLOGY

Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer

(2018) Valsamo Anagnostou et al.   CANCER RESEARCH

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies

(2018) Yi-Long Wu et al.   LUNG CANCER

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

(2018) Shu Yi Shen et al.   NATURE

Application of Cell-free DNA Analysis to Cancer Treatment

(2018) Ryan B. Corcoran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

(2018) Charu Aggarwal et al.   JAMA Oncology

There is still a role for cytology in the ‘liquid biopsy’ era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression

(2017) Eduardo Clery et al.   JOURNAL OF CLINICAL PATHOLOGY

A Comparison of Cell-Free DNA Isolation Kits

(2017) Laure Sorber et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

(2017) Marilyn M. Li et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

(2017) Biagio Ricciuti et al.   MEDICAL ONCOLOGY

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct detection of early-stage cancers using circulating tumor DNA

(2017) Jillian Phallen et al.   Science Translational Medicine

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling

(2017) Aadel A. Chaudhuri et al.   Cancer Discovery

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

(2016) M. Jamal-Hanjani et al.   ANNALS OF ONCOLOGY

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

(2016) J. C. Thompson et al.   CLINICAL CANCER RESEARCH

cMET Exon 14 Skipping: From the Structure to the Clinic

(2016) Nele Van Der Steen et al.   Journal of Thoracic Oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

(2016) Jeanne Tie et al.   Science Translational Medicine

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)

(2016) James L. Sherwood et al.   PLoS One

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

(2015) C. P. Paweletz et al.   CLINICAL CANCER RESEARCH

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

(2015) Kenneth S. Thress et al.   LUNG CANCER

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

(2015) Sacha Rothschild   Cancers

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

(2015) Richard B. Lanman et al.   PLoS One

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

(2014) S. Couraud et al.   CLINICAL CANCER RESEARCH

Guidance for laboratories performing molecular pathology for cancer patients

(2014) Ian A Cree et al.   JOURNAL OF CLINICAL PATHOLOGY

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

(2014) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

(2014) Aaron M Newman et al.   NATURE MEDICINE

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids

(2013) Karen Page et al.   PLoS One